Department of Medicine, University of Utah School of Medicine, Salt Lake City, Utah 84112.
Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah 84112; email:
Annu Rev Med. 2018 Jan 29;69:421-436. doi: 10.1146/annurev-med-052716-031710. Epub 2017 Nov 3.
Antiretroviral therapy (ART) has rendered HIV-1 infection a treatable illness; however, ART is not curative owing to the persistence of replication-competent, latent proviruses in long-lived resting T cells. Strategies that target these latently infected cells and allow immune recognition and clearance of this reservoir will be necessary to eradicate HIV-1 in infected individuals. This review describes current pharmacologic approaches to reactivate the latent reservoir so that infected cells can be recognized and targeted, with the ultimate goal of achieving an HIV-1 cure.
抗逆转录病毒疗法（ART）使 HIV-1 感染成为一种可治疗的疾病；然而，由于复制能力强的潜伏前病毒在长寿静止 T 细胞中持续存在，ART 并不能治愈。为了在感染个体中根除 HIV-1，需要针对这些潜伏感染的细胞的策略，以允许免疫识别和清除这个储库。这篇综述描述了目前药理学方法来重新激活潜伏储库，以便可以识别和靶向受感染的细胞，最终目标是实现 HIV-1 的治愈。
